Drugs / rhBNP
rhBNP
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01625403 | Jul 2012 → Dec 2013 | acute kidney injury, heart failure | Shanghai Chest Hospital | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04157868 | Nov 2019 → Sep 2022 | ST-elevation myocardial infarction | RenJi Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04033861 | Jun 2019 → Aug 2020 | ST-elevation myocardial infarction | RenJi Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07086287 | Aug 2025 → Nov 2026 expected | — | The First Affiliated Hospital of Anhui Medical University | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02742909 Comparator | Dec 2015 → Dec 2018 | pulmonary hypertension | LI ZHAO | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhBNP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04033861 ↗ |
| Known as | BNP | “Lyophilized recombinant brain natriuretic peptide (BNP) is an exogenous peptide synthesized by artificial recombination technology” PMID 38188212 ↗ Dec 2023 |
| Known as | recombinant brain natriuretic peptide | “Lyophilized recombinant brain natriuretic peptide (BNP) is an exogenous peptide synthesized by artificial recombination technology” PMID 38188212 ↗ Dec 2023 |
| Known as | recombinant human B-type natriuretic peptide | “recombinant human B-type natriuretic peptide (rhBNP)” NCT01625403 ↗ |
| Known as | recombinant human BNP | “patients of the observation group were administered the recombinant human BNP injection for the same time-period” PMID 38188212 ↗ Dec 2023 |
| Known as | recombinant human brain natriuretic peptide | “Lyophilized recombinant human brain natriuretic peptide: A promising therapy in patients with chronic heart failure.” PMID 38188212 ↗ Dec 2023 |
| Modality | Peptide | “recombinant human B-type natriuretic peptide (rhBNP)” NCT01625403 ↗ |
| Route | Intravenous | “intravenous administration of rhBNP 0.01 µg/kg/min” NCT01625403 ↗ |